
The Library Media — National & World · National Desk
By Eleanor Ever Loyal
The White House is dropping Heidi Overton’s nomination to lead the Food and Drug Administration because of a lack of congressional support, Axios reported Tuesday, November 17, citing information obtained by the news organization.
The decision means the Trump administration will need to identify another candidate to lead the agency as Health and Human Services Secretary Robert F. Kennedy Jr. seeks to advance his Make America Healthy Again agenda, according to Axios.
Overton’s nomination had advanced to a confirmation hearing before the Senate Health, Education, Labor and Pensions Committee on September 24, 2026. The White House decision, as reported by Axios, ends that nomination process without a successor identified in the report.
Axios did not name a replacement candidate or provide a vote count indicating the extent of the opposition to Overton’s nomination. The report also carried no White House statement explaining the decision.
The administration will now have to find another nominee for the FDA’s top post, Axios reported.
Update — Tuesday, November 17, 2026, 5:46 p.m. PT: The White House has now formally withdrawn Heidi Overton’s nomination to lead the Food and Drug Administration, turning the move reported earlier Tuesday into an official act.
The withdrawal came on the eve of a scheduled vote in the Senate Health, Education, Labor and Pensions Committee, where Overton had been set to face the panel on Wednesday. The Hill reported that the nomination was withdrawn amid opposition from Senate Republicans.
The withdrawal was confirmed by a White House official and reported by The Hill, NBC News, Fox News and The Guardian. It confirms the reporting this story first carried, based on Axios’s account that the White House was dropping the nomination for lack of congressional support.
Eleanor Ever Loyal
National Desk, The Library Media
From The Library — the estate of our family.
Follow Us